Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

This study has been completed.

Sponsor:

Information provided by:

Wyeth is now a wholly owned subsidiary of Pfizer

ClinicalTrials.gov Identifier:

NCT00167999

First received: September 11, 2005

Last updated: March 14, 2007

Last verified: March 2007

History of Changes

Purpose

To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units

Condition	Intervention	Phase
Gram-Positive Bacterial Infections Escherichia Coli Infections Klebsiella Infections	Drug: piperacillin-tazobactam	Phase 4


Study Type:	Observational
Study Design:	Observational Model: Case Control Observational Model: Natural History Time Perspective: Longitudinal Time Perspective: Prospective
Official Title:	Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.

Resource links provided by NLM:

MedlinePlus related topics: Bacterial Infections

Drug Information available for: Piperacillin sodium Piperacillin Tazobactam

Genetic and Rare Diseases Information Center resources: Klebsiella Infection

U.S. FDA Resources

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:


Estimated Enrollment:	200
Study Start Date:	February 2005

Eligibility


Ages Eligible for Study:	15 Years and older (Child, Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Eligible patients of either sex, 15 years of age or older
Patients who are admitted to the department of hematology and oncology
Provide written informed consent

Exclusion Criteria:

Patients who have hypersensitivity to β-lactam antibiotics
Female who are pregnant or breast-feeding
Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00167999

Locations


Korea, Republic of

Seoul, Korea, Republic of, 133-792

Sponsors and Collaborators

Wyeth is now a wholly owned subsidiary of Pfizer

Investigators


Study Director:	Medical Monitor	Wyeth is now a wholly owned subsidiary of Pfizer

More Information


ClinicalTrials.gov Identifier:	NCT00167999 History of Changes
Other Study ID Numbers:	0910X-101676
Study First Received:	September 11, 2005
Last Updated:	March 14, 2007
Health Authority:	Korea: Food and Drug Administration

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:


Bacterial Infections

Additional relevant MeSH terms:


Infection Communicable Diseases Bacterial Infections Gram-Positive Bacterial Infections Klebsiella Infections Escherichia coli Infections Enterobacteriaceae Infections Gram-Negative Bacterial Infections Tazobactam	Penicillanic Acid Piperacillin Piperacillin, tazobactam drug combination Anti-Bacterial Agents Anti-Infective Agents Beta-Lactamase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 29, 2016

To Top